Atara Biotherapeutics (ATRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Atara Biotherapeutics Inc (NASDAQ:ATRA) shares are trading higher by 30.7% to $8.87 Wednesday morning. The company announced a $36 million registered direct offering of 758,900 shares at $8.25 per ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two ...